Skip to main content
Premium Trial:

Request an Annual Quote

NIH to Fund Two-Year High-Risk Studies

NEW YORK (GenomeWeb News) – The National Institutes of Health will give grants of up to $200,000 per year over two years to fund research into new scientific ideas and tools that can "substantially advance" biomedical or clinical research, including genomics technologies research at the National Human Genome Research Institute.

The aim of the Exploratory/Developmental Research Grant Program is to encourage exploratory and developmental research efforts by supporting them in their early stages. These programs could involve high-risk efforts that could lead to a breakthrough in some specific areas.

A breakthrough could involve development of new techniques, agents, methodologies, models, or applications that could have "a major impact" on biomedical, behavioral, or clinical research, according to NIH.

Direct costs for these grants are limited to $275,000 over two years, but the funding is not aimed at supporting projects in areas that are well-established or to support long-term projects.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.